Monica A. Totir
University of California, Berkeley(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Enzyme Structure and Function, Yersinia bacterium, plague, ectoparasites research, Phenothiazines and Benzothiazines Synthesis and Activities
Most-Cited Works
- → High Resolution Crystal Structures of the trans-Enamine Intermediates Formed by Sulbactam and Clavulanic Acid and E166A SHV-1 β-Lactamase(2005)72 cited
- → Tazobactam Forms a Stoichiometric trans-Enamine Intermediate in the E166A Variant of SHV-1 β-Lactamase: 1.63 Å Crystal Structure,(2004)69 cited
- → Following the Reactions of Mechanism-Based Inhibitors with β-Lactamase by Raman Crystallography(2003)67 cited
- → Rational Design of a β-Lactamase Inhibitor Achieved via Stabilization of the trans-Enamine Intermediate: 1.28 Å Crystal Structure of wt SHV-1 Complex with a Penam Sulfone(2006)54 cited
- → Effect of the Inhibitor-Resistant M69V Substitution on the Structures and Populations of trans-Enamine β-Lactamase Intermediates(2006)50 cited
- → Sulbactam Forms Only Minimal Amounts of Irreversible Acrylate-Enzyme with SHV-1 β-Lactamase(2007)50 cited
- → Different Intermediate Populations Formed by Tazobactam, Sulbactam, and Clavulanate Reacting with SHV-1 β-Lactamases: Raman Crystallographic Evidence(2009)44 cited
- → Macro-to-Micro Structural Proteomics: Native Source Proteins for High-Throughput Crystallization(2012)41 cited
- → Raman Crystallographic Studies of the Intermediates Formed by Ser130Gly SHV, a β-Lactamase that Confers Resistance to Clinical Inhibitors(2007)23 cited
- → Why Clinically Used Tazobactam and Sulbactam Are Poor Inhibitors of OXA-10 β-Lactamase: Raman Crystallographic Evidence(2008)16 cited